The sage continue...
Tuesday April 23, 4:00 pm Eastern Time
Press Release
SOURCE: Corvas International, Inc.
Corvas Announces Findings of Preliminary Analyses Of Stroke Trial of UK-279,276
SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Corvas International, Inc. (Nasdaq: CVAS - news) announces that preliminary analyses of the multi-center Phase IIb study of UK-279,276 (formerly known as Neutrophil Inhibitory Factor, or rNIF) being conducted by Pfizer Inc (NYSE: PFE - news) have been completed. Full analysis of the comprehensive and complex dataset from this trial in acute stroke patients is ongoing. Decisions regarding the further development of UK-279,276 will be made upon completion of the full analysis. However, the results from the preliminary analyses of the data relating to the primary endpoint, which represent a small fraction of the predefined statistical analyses, do not support initiation of a Phase III study in stroke. The final results from this trial will be reported following complete data analysis and review, which the company hopes will be available mid-2002. <snip> |
